EMBECTA CORP. (EMBC) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $139.40M; Long-term Debt, Excluding Current MaturitiesUSD $1.32B; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $139.40M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $9.50M; Long-term Debt, Excluding Current MaturitiesUSD $1.32B; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $9.50M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $9.50M; Long-term Debt, Excluding Current MaturitiesUSD $1.35B; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $9.50M.
- 2025-09-30: Long-term Debt, Current MaturitiesUSD $9.50M; Long-term Debt, Excluding Current MaturitiesUSD $1.39B; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
EMBECTA CORP. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Debt, Long-term and Short-term, Combined Amount USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $139.40M | $1.32B | (m) | $139.40M | $9.50M | $618.00M | $700.00M | (m) | (m) | $2.40M | $1.47B | $14.20M | (m) | (m) |
| 2026-03-31 | $9.50M | $1.32B | (m) | $9.50M | $9.50M | $618.00M | $700.00M | (m) | (m) | $4.80M | $1.34B | $15.40M | (m) | (m) |
| 2025-12-31 | $9.50M | $1.35B | (m) | $9.50M | $9.50M | $653.20M | $700.00M | (m) | (m) | $7.10M | $1.38B | $16.90M | (m) | (m) |
| 2025-09-30 | $9.50M | $1.39B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $1.40B | $9.50M | $9.50M | $9.50M | $688.30M | $700.00M | $0.00 | (m) | $1.42B | $18.60M | (m) | (m) |
| 2025-06-30 | $9.50M | $1.46B | (m) | $9.50M | $9.50M | $9.50M | $758.20M | (m) | (m) | $2.40M | $1.49B | $20.80M | (m) | (m) |
| 2025-03-31 | $9.50M | $1.51B | (m) | $9.50M | $9.50M | $9.50M | $833.30M | (m) | (m) | $4.80M | $1.54B | $22.90M | (m) | (m) |
| 2024-12-31 | $9.50M | $1.53B | (m) | $9.50M | $9.50M | $9.50M | $833.30M | (m) | (m) | $7.10M | $1.57B | $24.70M | (m) | (m) |
| 2024-09-30 | $9.50M | $1.57B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $1.57B | $9.50M | $9.50M | $9.50M | $9.50M | $863.30M | $700.00M | (m) | $1.60B | $26.50M | (m) | (m) |
| 2024-06-30 | $9.50M | $1.59B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $2.40M | $1.63B | $28.30M | (m) | (m) |
| 2024-03-31 | $9.50M | $1.59B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $4.80M | $1.63B | $29.70M | (m) | (m) |
| 2023-12-31 | $9.50M | $1.59B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $9.50M | $1.63B | $31.00M | (m) | (m) |
| 2023-09-30 | $9.50M | $1.59B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | $9.50M | $9.50M | $9.50M | $9.50M | $9.50M | $1.59B | (m) | $1.64B | $32.40M | (m) | (m) |
| 2023-06-30 | $9.50M | $1.59B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $2.40M | $1.64B | $33.60M | (m) | (m) |
| 2023-03-31 | $9.50M | $1.60B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $4.80M | $1.64B | $35.00M | (m) | (m) |
| 2022-12-31 | $9.50M | $1.60B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $7.10M | $1.64B | $36.30M | (m) | (m) |
| 2022-09-30 | $9.50M | $1.60B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | $9.50M | $9.50M | $9.50M | $9.50M | $9.50M | $1.60B | (m) | $1.65B | $37.70M | (m) | (m) |
| 2022-06-30 | $9.50M | $1.60B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $2.40M | $1.65B | $38.90M | (m) | (m) |
| 2022-03-31 | $9.50M | $1.40B | (m) | $9.50M | $9.50M | $9.50M | $9.50M | (m) | (m) | $4.80M | $1.45B | $36.80M | (m) | $197.00M |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2021-09-30 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |